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Abstract
A series of copper complexes were synthesized from benzo[d][1,3]dioxole-5-carbaldehyde
(piperonal) thio-semicarbazones (RHpTSC where R=H, CH3, C2H5 or C6H5 (Ph)). The
complexes show interesting variations in geometry depending on the thiosemicarbazone; a
dinuclear complex [Cu(HpTSC)Cl]2, a mononuclear complex [Cu(RHpTSC)2Cl2] (R=CH3 or
C2H5) and another mononuclear complex [Cu(PhHpTSC)(PhpTSC)Cl] was generated. The
complexes bind in a moderately strong fashion to DNA with binding constants on the order of
104M‒1. They are also strong binders of human serum albumin with binding constants near 104
M‒1. The complexes show good in vitro cytotoxic profiles against two human colon cancer cell
lines (HCT-116 and HT29) and two human breast cancer cell lines (MCF-7 and MDA-MB-231)
with IC50 values in the low millimolar concentration range.

Human serum albumin; Thiosemicarbazones; Anticancer; DNA binding; Structural variation

Introduction
The synthesis and chemical investigations of thiosemicarbazones (TSCs) and their metal
complexes are of considerable importance because of their potentially beneficial medicinal
applications and a wide variation in their modes of bonding and stereochemistry [1–3]. The
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biological activity of thiosemicarbazones is related to their chelating ability with transition
metal ions. This chelating ability is a function of the unique characteristics of the mixed
hard–soft NS donor atoms in the structure. The structure of TSCs offer up a variety of donor
atom sets such that they are versatile ligands in both neutral and anionic forms. TSC ligands
exist as thione–thiol tautomers (although the proton lost to form the anion formally belongs
to the hydrazinic –NH group). The exploration of copper complexes as chemical nucleases
is well documented because they possess biologically accessible redox potentials and
relatively high nucleobase affinity. Copper(II) thiosemicarbazone complexes have been the
focus of investigation as metallodrugs for various medical applications for a long period of
time. These applications include use as anti-cancer drugs [3–6]. As with most drugs seeking
to arrest the development of cancer, the cellular targets for copper complexes are not exactly
defined and may be variegate. DNA is most certainly a possibility but the compounds are
likely to encounter other biomolecules such as proteins either at or en route to the site of
action. Consequently proteins in general would also be a distinct set of molecular targets. As
the principal extracellular protein of the circulatory system, human serum albumin (HSA)
serves as the major transporter of drugs as well as endogenous compounds [7]. It is well
understood that the distribution, free concentration and the metabolism of various drugs can
be significantly altered as a result of their binding to HSA. Since HSA serves as a transport
carrier for drugs, it is important to study the interactions of potential drugs with this protein.
Knowledge of interaction mechanisms between drugs and plasma proteins is of crucial
importance to the understanding of the pharmacodynamics and pharmacokinetics of a drug
or drug prospect.

Discussion
The experimental procedures are similar to those that we have reported [8]. The ligands
were synthesized as previously reported [8]. The reaction of the ligands with copper(II)
chloride produces complexes 1–4 as light yellow, or tan in the case of 4, solids (Scheme 1)
(also see Supplemental Information). The complexes have been characterized by elemental
analyses, conductimetry as well as ESR and infrared spectroscopy. Based primarily on
elemental analysis and supported by infrared data, we have observed a variegate set of
coordination geometries for the complexes based on the nature of the ligand. When the
ligand has the amino nitrogen unsubstituted the complex (1) that is formed is best
formulated as dimeric species in the solid state. The complex has two four-coordinate
copper centers linked by two chloride bridges with the thiosemicarbazone coordinated as the
anionic form.
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The ESR spectra of the complexes (Fig. 1) were recorded at 43 K in DMSO, using a Bruker
ELEXSYS 580 spectrometer. The spectra of the complexes reveal a lineshape that is typical
for Cu2+ with axial symmetry of g-tensor. Theoretical fitting of the spectra gives the
following magnetic resonance parameters; g-tensor: g =2.08276; and g =2.4140; hyperfine
interaction tensor with Cu nucleus (I=3/2): A =1.1·10‒2 cm‒1; A<10‒3 cm‒1; and hyperfine
interaction tensor with two equivalent nitrogens (I=1): A =1.3·10‒3 cm‒1; A <10‒3 cm‒1.
ESR data suggest that in DMSO solutions these complexes, including 1, are mononuclear
species in nature. This behavior is not unprecedented in copper thiosemicarbazone
chemistry. Krishna et. al. [9] observed a similar phenomenon in their study of binuclear
copper complexes of cuminaldehyde thiosemicarbazones.
The conductivity of millimolar solutions of 1 was 4.3 Ω‒1 cm2 mol‒1. This indicates the
non-electrolyte nature of this complex [10]. When the amino nitrogen is substituted with a
methyl (2) or ethyl (3) group the expected stoichiometry of the compound is observed. Once
more, conductivity values for the two complexes (2.81 Ω‒1 cm2 mol‒1 for 2 and 3.15 Ω‒1
cm2 mol‒1 for 3) are such that the octahedral formulation with both chlorides present in the
Inorg Chem Commun. Author manuscript; available in PMC 2013 February 22.
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coordination sphere is justified. Complex 4 with the phenyl-substituted amino nitrogen
provides the most curious coordination mode. We mentioned before that thiosemicarbazones
can undergo tautomerization and subsequent deprotonation of the thiol form allowing for a
mono-anionic ligand. We are proposing that in complex 4 both types of binding – neutral
and anionic – are present. The result is a five-coordinate (likely square pyramidal) copper
center. This proposal is based primarily on micro-analytical data (though the infrared data
lend some support). There is literature precedence for this type of mixed-mode binding.
Joseph [11] have suggested that copper(II) can complex 2-benzoylpyridine N(4)-phenyl
thiosemicarbazone in such a fashion although in their case one ligand is tridentate bearing
the anionic form and the other is a monodentate binder using the iminic nitrogen. Souza [12]
has reported that in the platinum complexes of 3,5-diacety1-1,2,4-triazol
bis(thiosemicarbazones) one arm of the ligand coordinates as the neutral thione form and the
other arm as the deprotonated thiol form.
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Thiosemicarbazones exhibit characteristic bands corresponding to various groups in specific
energy regions. Infrared spectrophotometry can be used to identify the coordinated form and
it was observed that the characteristic absorption peaks of all complexes are similar (Table
1). The presence of a band corresponding to N‒H group (the azomethinic nitrogen),
suggests the coordination of a thiosemicarbazone to the metal center in a neutral form, while
its absence, would be suggestive of deprotonation of the azomethinic proton in the
complexes. For 1, one would expect six bands (or three for exact symmetric geometry) in
the NH region for the NH2 and NH hydrogens. The presence of the four corresponding to
the terminal NH2 supports the formulation of the complexed ligands as the anionic form.
The presence of these bands in 2 and 3 supports the thione formulation of the ligand in those
complexes and they do not shift significantly on complexation. For complex 4 the presence
of three rather than two bands in this region and particularly the absence of the lower energy
band lend support to the idea that there are two forms of the thiosemicarbazone ligand
coordinated to the metal. The coordination sites can also be inferred the spectral bands
attributed to the C=N iminic and C=S thioamide IV groups. The ligands show a medium
intensity band at 1570–1600 cm‒1 that we ascribe to C=N and these are generally shifted to
lower energy upon complexation. The involvement of the thiocarbonyl group can similarly
be inferred from the wavenumber shifts that occur on binding.
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The redox behavior of the complexes has been studied by cyclic voltammetry at a platinum
disc electrode in 1 × 10‒3 M dichloromethane solutions containing 0.1 M
tetrabutylammonium hexafluorophosphate as the supporting electrolyte. The
voltammograms for the compounds are very similar. In the positive direction all the
complexes show two irreversible anodic peaks; at 300 mV/s the first occurs at +0.407 V for
1, +0.385 V for 2, +0.407 V for 3, and +0.375 V for 4 all relative to Ag/AgCl. This couple is
assumed to be the metal-based oxidation Cu(II)/Cu(III). While these values might appear
low, other works have reported similar values and have suggested that the redox process
associated with the oxidation of Cu(II) to Cu(III) may probably originate due to the presence
of the thione sulfur center [13]. We have noted for other copper complexes in our labs
(unpublished work) similar electrochemical behavior and it appears that the Cu(II)/Cu(III)
redox couple can merge with the redox couple of the oxidized ligand around +0.75 V. We
are also carrying out extensive square wave voltammetry in order to ascertain the separate
redox couple for the ligand and the Cu(II)/Cu(III) redox process. The second peak is illdefined and occur at +1.33 V for all the complexes except for 1 where it occur at +1.44 V.
We are not exactly sure of the nature of this couple but based on the constancy of the
potential we propose that it might be ligand based [13]. The single oxidation peak observed
for complex 1 would appear to support the EPR data that it is monomeric in the solution
phase. It should be noted that the lower scan rate (100 mV/s) the first peak is hardly
noticeable but becomes more pronounced as the scan rate is increased. (See Supplemental
Inorg Chem Commun. Author manuscript; available in PMC 2013 February 22.
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Information). Cyclic voltammetric studies of thiosemicarbazone ligands have shown the
existence of an irreversible cathodic peak at ‒1.06 V, assignable to the reduction of the
thione group of the thiosemicarbazone moiety [13]. In our complexes this peak appears at ‒
0.659 V, ‒0.609 V, ‒0.598 V and ‒0.587 V for 1, 2, 3 and 4 respectively.

Ethidium bromide competition experiment
We have investigated the reaction of the complexes with calf thymus DNA via a
fluorescence competition experiment. Ethidium bromide (EB) is a well-known dye that is
commonly used as a marker for nucleic acids by intercalating between the base pairs and
generating a fluorescent adduct. The fluorescence from the adduct may be quenched by
addition of a compound that can displace the EB from the binding sites on the DNA. This
quenching may be taken as evidence that the compound can bind to DNA. Using 3 as a
typical example, we can see from Fig. 2 that the complex can indeed reduce the fluorescence
of the EB-DNA solution by as much as 63%. A quantitative estimate of this quenching
behavior can be obtained by treating the data according to the Stern-–Volmer Eq. (1):

(1)
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In this equation F0 and F are the fluorescence intensities of the reaction solution in the
absence and presence of the metal compound. KSV is the Stern-Volmer quenching constant
which is the measure of the effectiveness of the complex as a quencher. The inset of Fig. 2
shows the Stern-Volmer plots and the linearity of the plots for 2 and 3 confirm the
quenching behavior. The values of the quenching constant seen in Table 2 are on the order
of 104 M‒1 indicating that these are moderately strong quenchers. The Stern-Volmer plot for
complex 1 shows a positive deviation from linearity at high concentrations of the complex.
The quenching of the fluorescence can occur by two common mechanisms – dynamic and
static quenching. The deviation from linearity is usually explained by suggesting that there
are multiple binding sites on the fluorophore or that both quenching mechanisms are
occurring simultaneously. The static contribution may be calculated from the following Eq.
(2):

(2)

NIH-PA Author Manuscript

where KD and KS are the dynamic and static quenching constants. (KS would actually
represent the formation constant for a dark complex between the quencher and the
chromophores). However a completely unambiguous assignment of KD and KS requires
fluorescence lifetime measurements [14] (though varying temperature can be used to
characterize the quenching as predominantly dynamic or static). We propose that for 1 the
static contribution is significant. This is inferred from the bimolecular quenching constant
(Kq in Eq. 1) calculated by using τ0 = 22 ns [15] for the EB-DNA complex. Keq for the
reactions are on the order of 1012 M‒1 s‒1 which is two orders of magnitude larger than the
limiting value of 1010 M‒1 s‒1 [16] considered the largest possible value in aqueous
solution.
To assess the strength of the binding Eq. 3 was employed to calculate the apparent binding
constant.

Inorg Chem Commun. Author manuscript; available in PMC 2013 February 22.
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In this equation KEB is the binding constant for ethidium bromide, taken as 1.2 × 106 M‒1
[17], and [Cu]50% is the concentration of the complex that causes a 50% reduction of the
initial fluorescence. These values are shown in Table 2 and range from 1.79 × 104 to 2.23 ×
104 M‒1 which suggest that the complexes are moderate to strong binders.

Reaction of the complexes with HSA

NIH-PA Author Manuscript

Human serum albumin (HSA) is the most abundant of the blood serum proteins occurring to
the extent of 0.63 mM [7]. The protein serves as a transport unit for a wide variety of
endogenous substances including drugs. In this study we investigated the binding of the
complexes to HSA using fluorescence spectroscopy. HSA has a well-known structure that
contains a single tryptophan residue that is responsible for the majority of the intrinsic
fluorescence of the protein. On excitation at 295 nm HSA has strong fluorescence emission
at 350 nm. This emission can be attenuated by a small molecule binding at or near the
tryptophan as this amino acid unit is quite susceptible to changes in its environment. As a
representative example Fig. 3a shows that addition of 2 to HSA can very efficiently reduce
the fluorescence of the solution. Moreover the wavelength of maximum fluorescence
increased to 369 nm from 344 nm after addition of 22.5 μM of the complexes. It has been
noted [18] that the polarity of the molecular environment around the tryptophan residue
affects the wavelength of maximum fluorescence. So the 25 nm red shift is indicative of a
change to a more hydrophilic environment around the tryptophan fluorophore on addition of
the complexes. So we can conclude that the complexes in general can bind to HSA. We can
obtain a quantitative estimate of the strength of this binding by treating the data using the
Stern-Volmer equation (Eq. 1). Treatment of the data in this manner resulted in the plots
shown in Fig. 3b. It was observed that the plots were not linear as predicted from the
equation but showed significant positive deviations from linearity at higher concentration of
added metal complexes. There are two common explanations for this deviation. First the
HSA fluorescence can be quenched via both of the common quenching mechanism
operating simultaneously. Alternatively there might be multiple independent binding sites on
the HSA and they are not all accessible to the complexes. Under these circumstances, the
binding constant for the reaction can be obtained from a modified Stern-Volmer (MSV)
analysis. This involves treating the data using eq. 4:
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(4)

Here f = fraction of the fluorophore that is initially accessible to the complex which might
be interpreted as the number of binding sites. K is the effective quenching constant for the
fluorophore which can be taken as a binding constant assuming the decrease in fluorescence
comes from the interaction of the HSA with the complexes. Fig. 3C shows the plot of F0/F0–
F vs. 1/[Cu] from which we obtain K from the ratio of the intercept to the slope. The derived
binding constants are between 104 and 105 M‒1 indicating that they are strong binders
(Table 3).

Cytotoxicity studies
Compounds 1–4 were evaluated for their cytotoxicity against a panel of human tumor cell
lines (MCF-7, MDA-MB-231, HCT116 and HT29) by means of a colorimetric (MTS) assay
which measures mitochondrial dehydrogenase activity as an indication of cell viability [8].
Inorg Chem Commun. Author manuscript; available in PMC 2013 February 22.
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The effects of the compounds on the viability of these cells were evaluated after an exposure
period of 72 h. Cisplatin was used as comparison. All the complexes showed activity and
their corresponding IC50 values, corresponding to inhibition of cancer cell growth at the
50% level, are listed in Table 4. All the complexes show good cytotoxic profiles, with IC50
values generally in the low micromolar concentration range. As a general observation, the
monomeric octahedral complexes are more cytotoxic than either the dimeric or mixtautomer complexes. DNA is a major cellular target for metal complexes but given that there
is no significant difference in the DNA binding constants of the complexes, that ability to
bind DNA may not be an important reason for the difference in cytotoxicity. Between cell
lines there are no discernible trends; the compounds showed similar activities against the
MDA-MB-231 cells, which are estrogen receptor negative (ER(–)) and the ER(+) MCF-7
cells. There is a slightly more but still weakly defined trend present in the colon cell lines –
activity is higher in the HCT-116 cells. Considering the structural nature of the
thiosemicarbazone moiety, there appears to be no effect of the alkyl substituent on the amine
nitrogen on the cytotoxicity of the complexes. Another point to note is that under our assay
conditions the cells are in general more sensitive to the complexes than to the cisplatin
comparison.
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Fig. 1.

ESR spectra of compounds 1–4 in DMSO at 43 K. Inset=simulation ESR spectrum.
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Fig. 2.

Fluorescence emission spectra of the EB-DNA adduct in the absence and presence of
increasing amounts of 2, λex=520 nm, [EB]=0.33 μM, [DNA]=10 μM, [2] (μM): 0–32.5 in
2.5 μM increments. Temperature=303 K. Inset: Stern–Volmer plots for the complexes.
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Fig. 3.

Reactions with HSA. (a) Fluorescence emission spectra of HSA in the absence and presence
of increasing amounts of 2, λex=295 nm, [HSA]=5.0 μM and [2] (μM): 0 –22.5 in 2.5 μM
increments. Temperature=303.0 K (b) Stern-Volmer plots for the reaction of the complexes
at 308 K (c) Plot of the modified Stern–Volmer equation: F0/(F0–F) vs. 1/[Cu], for the
reaction of the complexes.
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Scheme 1.

Proposed structures of the complexes prepared in this study.
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Selected IRa data for the complexes.
Complex
Assignmentb

1

2

3

4

νNH

3415, 3397, 3236 (w), 3129

3389, 3131 (3339, 3147)

3366, 3130 (3373, 3135)

3331, 3300, 3086 (b) (3303, 3134)

νC=N

1592 (1589)

1573 (1590)

1564 (1589)

1589 (1596)

νC=S

1267, 831 (1290(w), 835)

1257, 839 (1284, 826)

1280, 830 (1314, 832)

1330, 851 (1319, 868)

w = weak, b = broad; values in parentheses are from the free ligands.

a

(ATR).

b

In cm‒1.
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Table 2

Binding constants for the interaction of the complexes with the EB-DNA adduct at 303 K.
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1

2

3

4

104 KSV (M‒1)

–

5.35

4.26

0.773

104 Kapp (M‒1)

2.23

1.79

1.91

0.406

104 Kq (M‒1 s‒1)

–

2.43

1.94

0.351

For complex 3 Kapp=1.53×104 M‒1 at 298 K.
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Table 3

Binding constants for the interaction of the complexes 1, 2 and 3 with HSA.
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104 K (M‒1)
Temperature (K)

1

2

3

293

4.46±0.50

5.35±0.31

1.64±0.24

303

12.7±0.40

7.81±0.23

2.26±0.50

308

82.1±0.2

12.7±0.06

2.43±0.63
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Table 4

Anti-proliferative activity of complexes 1–4 in panel of four human cancer cell lines.
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IC50 (μM)
Compound

MDA-MB-231

MCF-7

HCT-116

HT29

1

12.3±0.4

13.8±0.4

15.3±2.1

16.7±10.1

2

3.69±0.80

3.86±0.96

1.41±0.61

5.22±1.08

3

3.72±2.12

3.20±0.14

2.10±0.53

3.23±0.13

4

8.27±4.90

12.8±0.53

28.1±19.6

11.8±0.4

Cisplatin

730

506±86

3.10

24.3
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